Impact of Stent Recoil and Fracture in RCA Ostium Restenosis Following Stainless Steel or Cobalt Chromium Drug-Eluting Stent Implantation: A Serial Angiographic and IVUS Study

Atsushi Hirohata, Eiki Hirose, Tohru Ohe, Ryo Yoshioiaki
1The Sakakibara Heart Institute of Okayama, Okayama, Japan

Background: PCI procedure of RCA ostium stenosis is still a challenging issue due to high stent restenosis rate, possibly due to mechanical stress. However, mechanisms of restenosis following cobalt-chromium everolimus-eluting stent (EES) or stainless steel biolimus-eluting stent (BES) implantation have not been well clarified.

Methods: Sixty-four RCA ostium restenosis cases after 2nd generation DES (40 EES and 24 BES) were retrospectively analyzed. Serial (post initial stent and follow-up as revascularization) angiographic and IVUS evaluation were performed. In quantitative angiographic analysis (QCA), incidence of stent fracture (defined as complete separation of the stent segments and/or the absence of a stent strut on magnified fluoroscopic image), and partial (only one of the inner or outer struts was separated) and complete (both the inner and outer struts were separated) fracture type were evaluated. In IVUS, serial changes of minimum lumen and stent area (SA), and degree of stent recoil at minimum lumen area, defined as (follow-up SA - baseline SA / baseline SA *100), were also measured.

Results: Average follow-up phase was 14±10 months. Angiographic and IVUS morphometric parameters were similar in both groups at baseline. Significant lumen narrowing was observed from initial to follow-up phase in both groups (10.4±2.6 to 25.3±2.0, 10.7±5.4 to 2.4±2.3 mm2 in minimum lumen area, EES vs. BES, p<0.01 from baseline to follow-up for all). Stent fracture was more frequently observed in BES than EES (85 vs. 8%, p<0.01). In addition, complete fracture was highly observed in BES (29%) compared to EES (2%, p<0.05). In contrast, significant stent recoil was observed in EES only (11.8±5.7 to 9.0±1.5 mm2, p<0.01 from baseline to follow-up for EES, 11.6±4.8 to 11.3±3.4 mm2, p<0.05 for BES, and degree of stent recoil was significantly larger in EES than BES (23.8±2.6 vs. 2.5±0.6%, p<0.05). Additionally, there was only 1 BES and no EES case that both stent fracture and significant recoil, resulting in stent restenosis, was observed.

Conclusions: Stent fracture appears to be the major cause of RCA ostium restenosis after stainless steel BES, whereas stent recoil seems to be associated with restenosis after cobalt-chromium EES.

Multiple Predictors of In-Stent Restenosis with Clinical Presentation of Acute Coronary Syndrome After Drug-Eluting Stent Implantation

Soon Jun Hong1, Chul-Min Ahn1, Do-Sun Lim1, Jae Hyuong Park1, Cheol Woong Yu1
1Korea University Anam Hospital, Seoul, Korea, Republic of; 2Korea University, Seoul, Korea, Republic of; 3Yongdong General Hospital, Bucheon, Kyonggi

Background: Although in-stent restenosis (ISR) after drug-eluting stent (DES) is perceived to be a benign phenomenon, some patients with ISR showed clinical presentation of acute coronary syndrome (ACS). We sought to identify parameters influencing the likelihood of restenosis with clinical presentation of ACS after DES implantation.

Methods: Stented patients (n=3,817) with DESs were retrospectively reviewed for inclusion in the study from the Korea University PCI Database Registry. From this database, age and sex-matched 302 patients (7.9%) with ISR were assigned to either the Stable ISR group (n=156) or the ACS ISR group (n=146). Predictors of coronary restenosis with clinical presentation of ACS were identified with Cox regression analyses.

Results: The rate of risk factors such smoking, hypertension, and diabetes were similar between the 2 groups; moreover, the use of medications at baseline did not differ significantly between the 2 groups. More patients in the ACS ISR group showed two vessel diseases (n=70 [47.9%] vs. n=44 [28.2%], p<0.028, respectively). No significant differences in ISR pattern were noted between the 2 groups during the follow-up angiogram. Follow-up MMP-2 levels were significantly higher in the ACS ISR group when compared to the Stable ISR group (66.63±42.25 vs 57.386±2.423, P<0.011, respectively). Age (Hazard ratio [HR], 1.13; 95% confidence interval [CI], 1.02 to 1.26; P=0.024), diabetes (HR, 6.80; 95% CI, 1.16 to 3.99; P=0.034), the use of aspirin (HR, 0.005; 95% CI, 0.001 to 0.760; P=0.039), clopidogrel (HR, 0.010; 95% CI, 0.001 to 0.162; P=0.001), ACE inhibitor (HR, 0.210; 95% CI, 0.003 to 0.515; P<0.001), the use of first generation DES (HR, 1.130; 95% CI, 1.030 to 1.260; P=0.001), and MMP-2 level (HR, 1.120; 95% CI, 1.001 to 1.190; P=0.004) during follow-up were significant predictors of ISR with clinical presentation of ACS during the 3-year follow-up.

Conclusions: In the era of DES, older age, diabetes, the use of first generation DES, and increased MMP-2 levels were significant predictors of ISR with clinical presentation of ACS. In contrast, the use of aspirin, clopidogrel, high-dose statin, and ACE inhibitor prevented ISR with clinical presentation of ACS.
Conclusions: SF after BES occurs in 4.1% of lesions and is associated with higher rate of MACE, driven by higher rate of TLR.

TCT-455
Clinical Outcomes in the Percutaneous Coronary Intervention of In-Stent Restenosis with the XIENCE V Everolimus-Euting Stent
Michael Lee1, Tae Yang2, Ebitsham Mahmud3, Kyung Woo Park4, Hye-Soo Kim5, Moo-Hyun Kim6, George Dangas7, James Hermiller Jr.8, Mitchell Krucoff9, David Rutledge10
1UCLA School of Medicine, Los Angeles, CA, USA, 2Henry Ford Hospital, Detroit, MI, 3University of California, San Diego, San Diego, CA, 4Department of Internal Medicine and Cardiovascular Center, Seoul National University Hospital, Seoul, Korea, Republic of, 5Seoul National University College of Medicine, Seoul, Korea, Republic of, 6Duke University, Durham, NC, USA, 7Department of Cardiology, St Vincents Private Hospital, Darlinghurst, Sydney, Australia, 8San Francisco VA Medical Center, San Francisco, CA, 9Hanyang University College of Medicine, Seoul, Korea, Republic of, 10Abbott Vascular, Santa Clara, CA

Background: Though percutaneous coronary intervention with the XIENCE V® everolimus-eluting stent (EES, Abbott Vascular, Santa Clara, CA) for native coronary artery disease has favorable results compared to first generation drug-eluting stents, outcomes with EES for the treatment of in-stent restenosis (ISR) are unknown. The objective of this study is to evaluate the safety and efficacy of XIENCE V® for the treatment of ISR.

Methods: XIENCE V USA is a prospective observational multicenter registry evaluating clinical outcomes in patients who received treatment with EES. In this study, we present the 1-year clinical outcomes in patients who received EES for the treatment of ISR and non-ISR in this registry. The primary outcome was the composite of target lesion failure (defined as cardiac death, target vessel myocardial infarction, or target lesion revascularization). Secondary outcomes were myocardial infarction, target lesion revascularization, and stent thrombosis.

Results: In this registry 383 patients (64±11 years old; 68.4% male) received revascularization for non-ISR lesions. At 1 year, the rate of clinical adverse events (Table) was higher in the ISR group compared to the non-ISR group, however, these differences ceased to exist when case-control matched patients in the non-ISR group were studied.

Conclusions: The treatment of ISR with EES appears to be safe and efficacious at 1-year follow-up. Compared to the non-ISR group, the rate of target lesion failure was much higher indicating a higher risk profile of these patients. However, these differences ceased to exist with case control matched controlling.

Table. Clinical outcomes at 1 year.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Target Lesion Failure (ARC MI)</td>
<td>12.5%</td>
<td>7.0%</td>
<td>10.0%</td>
</tr>
<tr>
<td>Myocardial Infarction (ARC)</td>
<td>7.2%</td>
<td>5.8%</td>
<td>7.1%</td>
</tr>
<tr>
<td>Target Lesion Revascularization</td>
<td>10.3%</td>
<td>2.9%</td>
<td>6.8%</td>
</tr>
<tr>
<td>Stent Thrombosis (ARC DEFINED)</td>
<td>1.7%</td>
<td>0.2%</td>
<td>0.7%</td>
</tr>
</tbody>
</table>

TCT-456
The Impact of Atherogenic Neointima on Long-term Clinical Outcomes: An Observational Study from the Optical Coherence Tomography Registry
Masaru Kuroda1, Toshiro Shinke2, Hiromasa Otake3, Tomoyami Takaya4, Masayuki Nakagawa5, Hiroshi Hariki6, Takayuki Otsu7, Taisuke Kitaguchi8, Manami Iwase9, Ryo Nishio10, Akiko Komizu11, Hiroshi Kinutani12, Hachidai Takahashi13, Daisuke Terashita14, Ken-ichi Hirata15
1Kobe University Graduate School of Medicine, Department of Cardiology, Kobe, Japan

Background: Pathological studies have revealed atherosclerotic neointima (AN) after stent implantation. However, the risk factor of neointimal hyperplasia and its impact on future clinical events remain unclear.

Methods: From the Kobe university OCT database, 137 consecutive patients (253 stents) who underwent OCT examination at >1 year after bare metal or first-generation drug-eluting stent implantation were enrolled. We assessed AN (neointima containing a diffuse border, signal-poor region with invisible struts underneath) by OCT and compared major adverse cardiovascular event (MACE; death, recurrent myocardial infarction and target lesion revascularization (TLR)) rate between +AN and −AN group.

Results: 38 patients had AN at follow-up OCT, who had higher LDL-cholesterol and hs-CRP (≥5th percentile, p=0.045) level. In multivariate logistic analysis, LDL-cholesterol and hs-CRP were the independent predictors of the presence of AN (OR 1.025 (P=0.011), OR 1.016 (P=0.045), respectively). The rate of MACE were significantly higher in +AN than in −AN for an average follow-up of 58 months after stenting. After multivariate cox hazard analysis, the presence of AN remained an independent risk factor of MACE (HR 2.345, 95% CI 1.010-5.440, P=0.047).

Conclusions: Increased LDL-cholesterol and hs-CRP level may be risk factors for AN progression in patients treated with coronary stents. In this study, the presence of AN assessed by OCT was independently associated with MACE at >1 year after stent placement, suggesting a need for careful clinical follow-up of patients with AN.

TCT-457
Is There A Difference In The Clinical Presentation Of Patients With In-Stent Restenosis Of First- Versus Second-Generation Drug-Eluting Stents?
Marco A. Magalhaes1, Saeer Minhas2, Salem Badr3, Israel Barbash4, Joshua P. Loh5, lakshmana Pendulya6, Hiroshi Kikubata7, Al Fazir Omar8, Rebecca Torgason9, Fang Chen10, Kenneth Kent11, William O. Suddath12, Lowell F. Satler13, Augusto Pichard14, Rom Walkman15
1MedStar Washington Hospital Center, Washington, DC, 2Medstar Washington Hospital Center, Washington, DC, 3Washington Hospital Center, Washington, DC, 4Washington Hospital Center, District of Columbia, DC, 5Washington Hospital center, washington, dc, 6Medstat Washington Hospital Center, Washington, DC, 7Medstar Heart Institute, Washington, District Of Columbia, 8Washington hospital center, Washington, DC, 9washington hospital center, Washington, United States, 10MedStar Health Research Institute, Washington, DC

Background: The clinical presentation of bare metal in-stent restenosis (ISR) is reported to be associated with high rates of morbidity, including myocardial infarction (MI). This study aimed to compare the clinical presentation and outcomes between patients treated with 1st- vs. 2nd-generation drug-eluting stents (DES) and presented with ISR on admission.

Methods: The study identified first episode 1st or 2nd-generation DES ISR patients who underwent re-intervention. The clinical presentation at admission was classified as non acute (asymptomatic or stable angina) or acute (unstable angina, Canadian Cardiovascular Society (CCS) III or IV and MI). We compared the 1st- vs. 2nd-gen DES ISR clinical presentation and the rates of major adverse cardiac events (MACE) as a composite of death, Q-wave MI and target lesion revascularization at 6 months. Results: Overall, 767 patients with 1095 DES ISR lesions (1st-gen DES n=526; 2nd-gen DES n=113) were selected. The mean age was 65 ±10 years and diabetics comprised 49%. Clinical presentation included asymptomatic/stable angina in 29%, unstable angina in 62% and MI in 8%. Patients with 2nd-generation DES ISR were less likely to present as MI (13% vs. 5%; p<0.05) and with severe symptoms (73% vs. 49%; p<0.01) as compared to 1st-gen DES. The incidence of MACE in the 1st- and 2nd-gen DES at 6 months was 8% and 9%, respectively (p=1.0).

Conclusions: 2nd-generation DES ISR clinical presentation appears to be more benign with less frequency of MI and CCS III or IV symptoms compared to 1st-generation DES. The rates of MACE were similar at 6 months.

TCT-458
Angiographic localized haziness after drug-coated balloon angioplasty in de-novo lesions does not increase the risk of acute coronary thrombosis
Theresa Weichert1, Annette Fenger2, Philip Steen3, Klaus Bonaventura1
1Klinikum Ernst von Bergmann, Potsdam, Germany

Background: Clinical studies demonstrated the effectiveness and safety of drug-coated balloon (DCB) in various clinical scenarios and support the use of paclitaxel-coated balloon for the treatment of in-stent restenosis, of small coronary arteries and bifurcation lesions. A few small scale studies have reported excellent immediate and short term results of DCB use compared to non-coated balloon for de-novo lesions. Initial angiographic

B140 JACC Vol 62/18/Suppl B | October 27–November 1, 2013 | TCT Abstracts/POSTER/In-stent Restenosis and Stent Thrombosis